Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664937 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL11851404 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL10816721 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL8967917 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL11849011 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL5858660 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL10481688 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL11847945 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| SCHEMBL11855053 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD | |
| Laurocapram SCHEMBL23347 | 0.98 | ALOX5 (0.46) | L3MBTL1GAARAB9AALOX5PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-4424210-A | Vehicle composition containing 1-substituted azacycloalkan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4423040-A | Vehicle composition containing 1-substituted azacyclohexan-2-ones | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4415563-A | TOPICAL APPLICATION OF MEDICINE; COSMETICS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0077078-A1 | Method for improved plant pest control | Whitby Research Incorporated (US) | 1983-04-20 | — | — | EP | disclosed |
| US-4316893-A | USED FOR TOPICAL APPLICATION WITH A PHYSIOLOGICALLY ACTIVE AGENT | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4044001-A | Process for preparing α-chloro-ε-caprolactam | ALLIED CHEMICAL CORPORATION (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | L3MBTL1 4545/4885GAA 2752/4885RAB9A 1747/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | L3MBTL1 3812/4885GAA 3188/4885RAB9A 839/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | L3MBTL1 4545/4885GAA 2752/4885RAB9A 1747/4885 |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | L3MBTL1 4157/4885GAA 785/4885RAB9A 3821/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | L3MBTL1 4862/4885GAA 2993/4885RAB9A 3043/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | L3MBTL1 3999/4885GAA 1179/4885RAB9A 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.